| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT6A |
| Uniprot No | P02538 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-564aa |
| 氨基酸序列 | ASTSTTIRSHSSSRRGFSANSARLPGVSRSGFSSVSVSRSRGSGGLGGACGGAGFGSRSLYGLGGSKRISIGGGSCAISGGYGSRAGGSYGFGGAGSGFGFGGGAGIGFGLGGGAGLAGGFGGPGFPVCPPGGIQEVTVNQSLLTPLNLQIDPTIQRVRAEEREQIKTLNNKFASFIDKVRFLEQQNKVLETKWTLLQEQGTKTVRQNLEPLFEQYINNLRRQLDSIVGERGRLDSELRGMQDLVEDFKNKYEDEINKRTAAENEFVTLKKDVDAAYMNKVELQAKADTLTDEINFLRALYDAELSQMQTHISDTSVVLSMDNNRNLDLDSIIAEVKAQYEEIAQRSRAEAESWYQTKYEELQVTAGRHGDDLRNTKQEIAEINRMIQRLRSEIDHVKKQCANLQAAIADAEQRGEMALKDAKNKLEGLEDALQKAKQDLARLLKEYQELMNVKLALDVEIATYRKLLEGEECRLNGEGVGQVNISVVQSTVSSGYGGASGVGSGLGLGGGSSYSYGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKYTTTSSSSRKSYKH |
| 预测分子量 | 91.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KRT6A重组蛋白的3篇参考文献摘要概括：
---
1. **文献名称**: *"Recombinant expression and functional characterization of keratin 6A in epithelial integrity maintenance"*
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达了重组KRT6A蛋白，并验证了其在体外细胞模型中对上皮细胞骨架稳定性的作用。结果显示，KRT6A重组蛋白可增强细胞机械应力耐受性，支持其在皮肤屏障功能中的关键角色。
2. **文献名称**: *"Structural analysis of recombinant human KRT6A and its pathogenic mutations in pachyonychia congenita"*
**作者**: Lee S, et al.
**摘要**: 通过杆状病毒系统表达重组人KRT6A蛋白，结合X射线晶体学解析其结构，揭示了与先天性厚甲症相关的突变位点如何破坏角蛋白二聚化，导致细胞结构异常。
3. **文献名称**: *"Development of a keratin 6A recombinant protein-based assay for screening epidermal differentiation modulators"*
**作者**: Wang Y, et al.
**摘要**: 研究利用哺乳动物细胞表达体系制备高纯度KRT6A重组蛋白，并建立体外筛选平台，发现其表达水平与表皮分化标志物(如loricrin)正相关，为皮肤病药物开发提供工具。
---
以上文献均为虚构示例，实际研究中建议通过PubMed或Google Scholar以关键词“KRT6A recombinant protein”检索最新论文。
**Background of KRT6A Recombinant Protein**
Keratin 6A (KRT6A) is a type II intermediate filament protein encoded by the *KRT6A* gene, belonging to the keratin family essential for maintaining structural integrity in epithelial cells. It pairs with type I keratins (e.g., KRT16/KRT17) to form heteropolymeric networks, providing mechanical resilience to tissues like skin, nails, and mucosal surfaces. KRT6A is predominantly expressed in stratified epithelia and is upregulated during wound healing, hyperproliferative states, and stress responses, playing roles in cell migration, proliferation, and signaling.
Mutations in *KRT6A* are linked to genetic disorders such as pachyonychia congenita (PC) and focal non-epidermolytic palmoplantar keratoderma, characterized by painful calluses, nail dystrophy, and oral lesions. These pathogenic variants disrupt keratin filament assembly, leading to cellular fragility and dysregulated stress responses. Studying KRT6A's function and dysfunction is thus critical for understanding epithelial pathophysiology.
Recombinant KRT6A protein is produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) to obtain purified, functional protein for *in vitro* studies. It enables researchers to investigate keratin interactions, filament formation, and mutation effects in controlled environments. Recombinant forms are also used to develop antibodies, study protein-protein interactions, and model disease mechanisms. Additionally, it serves as a tool for drug screening, aiming to identify compounds that stabilize keratin networks or mitigate mutation-related defects.
Current research leverages KRT6A recombinant protein to explore its role beyond structural support, including inflammatory signaling and apoptosis regulation. Challenges remain in mimicking post-translational modifications and achieving native-like filament assembly *in vitro*. Nonetheless, recombinant KRT6A remains vital for advancing therapeutic strategies for keratin-related disorders and understanding epithelial biology.
×
